Newest: Transition to molecular diagnostics: How agricultural expertise can help maintain...
Latest news: Game-changing real-time detection: Improved ACS diagnosis in emergency departments
Latest news: 5 upcoming webinars to support your research
The latest news: MOBILion Systems launched a red carpet for MOBIE in his hometown of American Volkswagen Association...
Latest news: "Cooperation makes it easier to overcome challenges"
New: Volumetric Titration: A step-by-step guide to correct results
Latest News: Oxford Instruments Announces 2021 Sir Martin Wood Award Winner
Game-changing point-of-care testing: Improving ACS diagnosis in the emergency department
Transition to molecular diagnostics: how agricultural expertise can help keep COVID-19...
Thermo Fisher Scientific advances proteomics by choosing collaborations and new analyses...
LGC develops new Berlin base to expand nucleic acid therapy capabilities
5 Upcoming webinars to support your research
Volumetric titration: a step-by-step guide to correct results
A guide to efficient and environmentally friendly cannabinoid purification
Improve LC-MS accessibility to simplify biotherapeutic analysis
Weighed according to the European Pharmacopoeia (Ph. Eur.)
siRNA screening: the development of a hit stratification strategy
How to use 3D cell culture model to reduce the cost and time of setting up reproducible HTS/HCS
Develop a sensitive and reliable SARS-CoV-2 wastewater analysis program based on qRT-PCR
How to buy next-generation sequencing
Virtual Cancer and Immunology Research Summit
In order to meet the need to make adeno-associated virus (AAV) production more efficient and scalable, Thermo Fisher Scientific has launched the integrated Gibco AAV-MAX Helper Free AAV production system. This complete and optimized solution simplifies the AAV carrier production workflow. The all-in-one AAV-MAX system improves productivity and cost efficiency by using Viral Production Cells 2.0 (a new, clone-recorded, 293F-derived mammalian cell line) to provide high virus titers.
AAV is essential for gene therapy; more than 1,300 unique gene therapy products are currently being developed, nearly half of which rely on AAV. The ability to scale production is essential to reduce costs and accelerate the commercialization of research.
Amy Butler, President of Thermo Fisher Biosciences, said: “The effectiveness and safety of AAV make it an ideal therapeutic vector and one of the preferred biological delivery methods to achieve the latest breakthroughs in gene therapy. The new AAV production system is our end-to-end Part of the workflow solution to meet the growing demand for cost-effective and scalable viral vector production. Access to products and services specifically designed for cell and gene therapy research, and focus on clinical manufacturing, empowering us with biotechnology and biology Power of Pharmaceutical Partners."
The AAV-MAX system has been developed for expansion from shake flasks to bioreactors. The system is designed to be combined with the active development of compliant reagents to simplify the transition from research to commercial manufacturing. Compared with a mammalian production system based on polyethyleneimine (PEI), this system can save viral vector researchers and developers an average of 25% in the use of plasmid DNA and 50% in production costs. When used with Thermo Fisher's expanded gene therapy product portfolio, developers can smoothly upgrade to commercial production to help provide treatment for patients.
Want to send the latest science news directly to your inbox? Become a SelectScience member now for free >>
LentiArray™ Human Whole Genome CRISPR L...
LentiArray™ Human Druggable CRISPR Libr...
LentiArray™ Human Whole Genome CRISPR L...
LentiArray™ Human Druggable CRISPR Libr...
原文
提供更好的翻译建议
<="" div="">
<="" p="">
<="" div="">
<="" p="">